Two studies published this week in JAMA report that a blood protein fragment, eMTBR-tau243, identified advanced-stage chronic traumatic encephalopathy (CTE) in former American football players whose diagnosis was later confirmed by autopsy — the first blood-based signal strong enough to distinguish severe CTE from healthy and early-stage cases in living people, ESPN reported.
The test is not approved and cannot yet diagnose early disease.
Until now, CTE — a neurodegenerative disease linked to repeated blows to the head in football and other contact sports — could be diagnosed only after death, by examining brain tissue at autopsy. That barrier has stalled every avenue of treatment research: without a way to measure the disease in a living patient, scientists cannot recruit people into clinical trials or track whether an experimental drug is working.
A validated blood biomarker would change that calculus. “It’s a game-changer,” said Michael Alosco, co-senior author of the study and co-director of clinical research at Boston University’s CTE Center, in a statement carried by WGBH. “If future studies validate these findings, this blood test will allow us to detect CTE with a high level of accuracy and open the doors to clinical trials and treatment.”
How the Blood Protein Revealed the Disease
The Boston University and Banner Health study, published Thursday in JAMA, examined 21 deceased football players who had donated blood while alive and their brains after death. Autopsies confirmed CTE in 18 of the 21, including 16 with high-stage disease.
In blood samples drawn closest to death, researchers found markedly higher concentrations of endogenously cleaved microtubule-binding region tau — eMTBR-tau — in players with advanced CTE, and found those same elevated levels absent in people with low-stage or no CTE.

Tau is a protein that forms tangles inside neurons, damaging and killing the cells; both CTE and Alzheimer’s disease involve toxic tau buildup. Alosco told The Boston Globe the contrast between groups was striking: “What was really quite striking was just the difference.”
A companion study from Washington University School of Medicine in St. Louis, published Friday, Nov. 13 in JAMA, independently identified the same fragment — eMTBR-tau243 — in 11 autopsy-confirmed CTE cases, according to Tech Times and The Guardian. Levels rose with disease severity, and the test separated advanced CTE from healthy controls with high accuracy but could not reliably identify early-stage disease.
Because both diseases share a mixed 3R/4R tau signature, the authors say a rising level alone would not distinguish CTE from Alzheimer’s; they recommend running an Alzheimer’s blood test alongside it.
“This is not going to be a standalone biomarker,” neuroscientist Chihiro Sato, who co-authored the St. Louis study, told The Guardian. “But if someone has a history of repeated head injury, tests negative for Alzheimer’s and this biomarker comes up, it might be CTE.”
No CTE Blood Test Exists for Public Use
- No CTE blood test is available to the public today. No test or treatment for CTE has been approved by the U.S. Food and Drug Administration.
- The signal so far applies only to advanced disease — the stage marked by memory loss, confusion, depression, irritability, and severe mood swings — not the symptom-free early stage.
- Former contact-sport athletes with memory or mood symptoms should still see a clinician: several conditions with similar symptoms, including sleep apnea, high blood pressure, and low testosterone, are treatable, as Harvard’s Rachel Grashow advised in Tech Times’ reporting.
Why Sample Size Shapes What Comes Next
Both research teams emphasize the work is in a “discovery phase.” Twenty-one and eleven participants are small numbers by the standards of diagnostic research, and the groups included very few people with early-stage CTE or no disease at all.
Dr. Monroe, an outside expert quoted by The Boston Globe who was not involved in the study, put the limitation plainly: “Before we know how this test performs, it must be studied in a broader group of people: those with and without a history of head impacts, with and without symptoms, followed over time.”
He added, “Ultimately, I do not think any single marker will solve this. The more realistic path is a combination of tools,” likely including brain imaging.
Alosco told ESPN he is “cautiously optimistic” a reliable test could be developed at some point in the next five years, and BU researchers see the biomarker as the missing prerequisite for treatment trials.
“You can’t have something like a clinical trial without being able to measure a pathology during life,” Annalise Miner, a BU researcher and study author, told WGBH. Michael Buckland, a clinical associate professor of pathology at the University of Sydney not involved in either study, called the work “a watershed moment for the field” in Scientific American’s reporting.

What the Numbers Show Across Both Studies
| Study | Participants | Autopsy-confirmed CTE | Key finding |
|---|---|---|---|
| Boston University / Banner Health (JAMA, Thursday) | 21 former football players | 18, including 16 high-stage | eMTBR-tau elevated only in advanced CTE |
| Washington University, St. Louis (JAMA, Nov. 13) | 11 autopsy-confirmed CTE cases | 11 | eMTBR-tau243 rose with severity; early-stage CTE not reliably detected |
FDA Clearance Requires Larger Validation Studies
The path from a discovery-phase biomarker to an FDA-cleared test runs through larger, longitudinal cohorts — and the timeline Alosco offers, roughly five years, assumes the finding holds. Prior attempts have had mixed results: in 2017, researchers reported using a brain scan to identify CTE in a living former NFL player, and scan-based diagnostics remain under study, ESPN reported.
A separate JAMA Network Open study from the DIAGNOSE CTE Research Project, published July 1, found the Alzheimer’s-linked biomarker plasma p-tau217 unlikely to help detect CTE, though useful for ruling out amyloid pathology, per Tech Times. Alzheimer’s blood testing, by contrast, is already entering the clinic: the FDA cleared C2N’s PrecivityAD2 mass-spectrometry blood test on Aug. 20.
The stakes behind the science are large. A study of nearly 400 NFL players whose brains were donated after death found 93.5% showed evidence of CTE, The Guardian reported, and more than 350 NFL players have been diagnosed with the disease posthumously. Separately, an October study of all deceased players estimated roughly three out of four who died between 2008 and 2023 most likely had CTE — the highest estimate so far, per NBC Boston.

Would Players Want to Know?
A living test raises questions the science cannot answer. Last summer, ESPN asked more than 30 current and former NFL players whether they would take a CTE test if one existed. “Yeah, I would,” Washington Commanders quarterback Marcus Mariota told ESPN. "I think because, ultimately, it gives insight to the rest of the NFL, to college kids, to high school kids of what we're getting ourselves into. Then yeah, absolutely.”
Minnesota Vikings safety Joshua Metellus saw it differently: “I probably wouldn’t want [the test] while I’m in the league, because I think it’ll change the way I play. But I know there’s a lot of guys who are very curious and would like to know.”
The findings also carry weight beyond American football. Legal action is continuing from living former rugby players diagnosed with Traumatic Encephalopathy Syndrome, including England World Cup winner Steve Thompson, The Guardian reported, and earlier this year the Professional Footballers’ Association recommended professionals head a ball no more than 10 times a week in training — and children under 12 not at all.
No Test to Request; Seek Evaluation for Treatable Conditions
There is no CTE blood test to request, and clinicians cannot order one; asking for “a CTE blood test” today would yield nothing, and no FDA-approved CTE diagnostic or treatment exists.
Former contact-sport athletes experiencing persistent memory loss, confusion, depression, irritability, or severe mood swings should seek evaluation for treatable conditions that mimic CTE symptoms, and any thoughts of self-harm warrant immediate professional help. The biomarker itself is a research tool, usable only within approved studies until larger validation trials are complete.
The blood test is the latest chapter for Boston University’s CTE Center, a research lab at the university’s School of Medicine that grew out of its Alzheimer’s Disease Center, established in 1996. In 2008, the Center joined with the U.S. Department of Veteran Affairs and the Concussion Legacy Foundation to form the VA-BU-CLF Brain Bank, the first tissue repository in the world dedicated entirely to studying CTE.
That bank remains the largest such repository focused on traumatic brain injuries, holding more than 600 donated brains, and the Center now houses 70 percent of global CTE cases. Its long-stated goal has been exactly what this week’s studies move toward: diagnosing CTE in living subjects.
For the families of the 21 donors, the science is already personal. Ron “Bogie” Edwards, who played at Utah State and later in the Canadian Football League, died last year at 79 and was among the study participants. “I am so excited that my dad’s final contribution to the world can potentially help millions,” his son, Rogue Edwards, told NBC Boston.

References
- ESPN, WGBH, NBC Boston, The Boston Globe, Tech Times, The Guardian, WBUR, Scientific American — original reporting on this story